home / stock / uncy / uncy news

UNCY News and Press, Unicycive Therapeutics Inc.

Stock Information
Company Name: Unicycive Therapeutics Inc.
Stock Symbol: UNCY
Market: NASDAQ
Website: unicycive.com
Menu
UNCY UNCY Quote UNCY Short UNCY News UNCY Articles UNCY Message Board
Get UNCY Alerts

News, Short Squeeze, Breakout and More Instantly...
UNCY - Unicycive Therapeutics files to sell 50M shares by holders

2024-07-05 16:11:06 ET More on Unicycive Therapeutics Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeutics Read the full article on Seeking Alpha ...
UNCY - Unicycive Therapeutics joins Russell Microcap Index

2024-07-01 07:19:17 ET More on Unicycive Therapeutics Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeutics Read the full article on Seeking Alpha ...

UNCY - Unicycive Therapeutics Joins Russell Microcap® Index

LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced it was included in the Ru...

UNCY - Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
UNCY - Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury...

UNCY - Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Ex...

UNCY - Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clin...
UNCY - Unicycive Therapeutics reports Q1 GAAP EPS of -$0.61

2024-05-14 12:36:52 ET More on Unicycive Therapeutics Unicycive rises 4% on $50M private placement Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeuti...

UNCY - Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings – LOS ALTOS, Calif., May 13, 2024 (GLOBE NEWSWI...

UNCY - 3 Top Penny Stocks to Buy for Explosive Returns: April Edition

2024-05-01 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the top penny stocks to buy can be rewarding. First, when it comes to penny stocks, you have to understand the high risk involved. As the U.S. Securities and Exchange Commissi...
Next 10